Holen Sie sich die Stockscreener-App
12.66
0.39%
-0.05
Handel nachbörslich:
12.50
-0.16
-1.26%
Tonix Pharmaceuticals Holding Corp Aktie (TNXP) Neueste Nachrichten
Tonix Pharmaceuticals (TNXP) Q2 2026 Earnings Call Transcript - AOL.com
TNXP Slips After Hours On Slower Than Expected Launch For Fibromyalgia Drug - Stocktwits
Why TNXP Stock Is Suddenly Back On Retail Radar - Stocktwits
Tonix Pharmaceuticals Holding Corp. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:TNXP) 2026-08-14 - seekingalpha.com
TNXP Stock Dives For Four Straight Sessions — Retail Eyes Drug Pipeline Payoff - Stocktwits
Sirenia Capital (TNXP) discloses 4.9% Tonix Pharmaceuticals stake including warrants - Stock Titan
AQR Capital discloses 5.54% ownership in Tonix Pharmaceuticals (TNXP) via Schedule 13G - Stock Titan
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - simplywall.st
Tonix Pharmaceuticals Holding Corp.Common Stock (NQ: TNXP - FinancialContent
Tonix Pharmaceuticals Holding Corp. (TNXP) stock price, news, quote and history - Yahoo Finance UK
Tonix Pharmaceuticals (TNXP) Revenue Surge Meets Persistent Cash Burn Concerns - Sahm
Tonix Pharmaceuticals at Canaccord Genuity conference: launch gains build By Investing.com - Investing.com UK
Tonix Pharmaceuticals at Canaccord Genuity conference: launch gains build - Investing.com India
Tonix Pharmaceuticals: TONMYA Refills Surge 207% As Coverage Reaches 136 Million U.S. Lives - Pulse 2.0
Tonix Pharma earnings beat by $0.27, revenue topped estimates - Investing.com Nigeria
Tonix Delivers A Beat, But The Real Test Starts Now (NASDAQ:TNXP) - seekingalpha.com
Raymond James raises Tonix Pharma stock price target on strong sales - Investing.com UK
Penny Stocks: What Does Tonix Pharmaceuticals (NASDAQ:TNXP) Update Signal? - Kalkine Media
Tonix Pharmaceuticals Holding Corp (TNXP) (Q2 2026) Earnings Cal - GuruFocus
Tonix Pharmaceuticals Holding Corp (TNXP) (Q2 2026) Earnings Call Highlights: TONMYA Surges ... - Yahoo Finance UK
Tonix Pharmaceuticals Q2 2026 Earnings Call Transcript - MarketBeat
Tonix Pharmaceuticals Q2 Earnings Call Highlights - MarketBeat
TNXP: Tonmya's launch fueled major Q2 revenue growth and pipeline progress, with cash runway into 2027 - TradingView
Earnings call transcript: Tonix beats Q2 2026 estimates as TONMYA sales surge - Investing.com Nigeria
Tonix Pharmaceuticals Holding Releases Q2 2026 Financial Results - AlphaStreet
TNXP: TONMYA sales nearly tripled in Q2 2026, driving revenue growth and supporting robust pipeline progress - TradingView
Tonix Pharmaceuticals (NASDAQ:TNXP) Announces Earnings Results - MarketBeat
TNXP: Q2 2026 net revenue reached $13.5M, driven by TONMYA's 197% QoQ sales growth - TradingView
Q2 2026 Tonix Pharmaceuticals Holding Corp Earnings Call Transcript - GuruFocus
Is Tonix Pharmaceuticals (TNXP) Overvalued After Q2 Earnings Rep - GuruFocus
TNXP Looks 584.3% Overvalued on GF Value™ - GuruFocus
Tonix Pharmaceuticals Holding Corp. 2Q 2026: Revenue $13.54M, EPS ($2.44) — 10-Q Summary - TradingView
Tonix Q2 FY26 net loss narrows to $40.55 million; product revenue rises to $13.54 million - Bitget
Tonix Pharmaceuticals posts $13.5M Q2 product revenue, $40.6M net loss - TradingView
Tonix Pharmaceuticals Reports Q2 Revenue of $13.5 Million - Quiver Quantitative
Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights - The Manila Times
TNXP: Q2 2026 revenue soared 575% year-over-year, driven by TONMYA sales and expanded coverage - TradingView
Tonix's Fibromyalgia Treatment Reaches 136M Covered Lives - Stock Titan
Tonix Pharmaceuticals Holding Corp (TNXP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Insider Buyers At Tonix Pharmaceuticals Holding Recover Some Losses, But Still Down US$57k - webull.com
TNXP Looks 587.4% Overvalued on GF Value™ - GuruFocus
TONIX PHARMACEUTICALS HLDG Q2 2026 Earnings Preview: Recent $TNXP Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
Tonix Pharmaceuticals Holding Corp. expected to post a loss of $2.70 a shareEarnings Preview - TradingView
The Technical Signals Behind (TNXP) That Institutions Follow - Stock Traders Daily
Tonix Pharmaceuticals to Participate in Upcoming Investor Conferences - The Manila Times
Tonix CEO Seth Lederman to Take Part in Two Investor Events - Stock Titan
Tonix Pharmaceuticals (TNXP) Expected to Release Earnings on Monday - MarketBeat
TNXP Looks 472.6% Overvalued on GF Value™ - GuruFocus
Tonix Pharmaceuticals Announces FDA Alignment on 3,300‑Participant Adaptive Phase 2 Lyme Study; TNX-4800 Dosing, 2027 Site Delivery - TradingView
Tonix Pharmaceuticals Announces FDA Alignment on Phase 2 Study Design for TNX-4800 Lyme Disease Prevention Trial - Quiver Quantitative
Tonix Pharmaceuticals Announces Positive Minutes from Type C FDA Meeting to Discuss Adaptive Phase 2 Field Study of TNX-4800, a Human, anti-OspA Monoclonal Antibody, to Prevent Lyme Disease in the U.S. - Yahoo Finance
Tonix Pharmaceuticals Holding Corp (TNXP) Cash Flow - TradingKey
Tonix Pharmaceuticals Holding Corp - TradingKey
Tonix Pharmaceuticals Holding Corp (TNXP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Tonix Pharmaceuticals Holding Corp. to Host Second Quarter 2026 Financial Results Conference Call and Webcast - Quiver Quantitative
Tonix to discuss second-quarter results on Aug. 10 call - Stock Titan
TNXP|Tonix Pharmaceuticals Holding Corp|Price:10.390|Chg%:+0.510 - TradingKey
1.80%
1.77%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):